(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual revenue growth rate of 11.97% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.71%.
Aurinia Pharmaceuticals's revenue in 2025 is $265,808,000.On average, 9 Wall Street analysts forecast AUPH's revenue for 2025 to be $37,577,196,126, with the lowest AUPH revenue forecast at $35,298,991,267, and the highest AUPH revenue forecast at $39,113,138,639. On average, 9 Wall Street analysts forecast AUPH's revenue for 2026 to be $43,363,678,261, with the lowest AUPH revenue forecast at $38,529,084,962, and the highest AUPH revenue forecast at $49,763,218,995.
In 2027, AUPH is forecast to generate $49,205,533,430 in revenue, with the lowest revenue forecast at $42,249,625,537 and the highest revenue forecast at $62,566,255,679.